INCY Incyte Corporation

66.25
-1.04  -2%
Previous Close 67.29
Open 66.61
Price To Book 7.82
Market Cap 14098539805
Shares 212,808,148
Volume 1,181,828
Short Ratio
Av. Daily Volume 1,614,550

SEC filingsSee all SEC filings

  1. 8-K - Current report 181203167
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181146953
  3. 8-K - Current report 181145510
  4. 8-K - Current report 181057928
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18981118

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2019.
Baricitinib
Atopic dermatitis
Phase 2 interim data at ESMO October 2018. ORR 40%.
INCB54828 (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 data due 2019.
INCB54828 (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 data due 2019.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2018.
Baricitinib
Psoriatic arthritis
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal Phase 2 trial initiation announced November 15, 2017.
Ruxolitinib (RESET-272)
Essential thrombocythemia
Phase 3 trial commenced June 2017.Expected completion 2H 2019.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 trial to be completed 2H 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
PDUFA date under priority review February 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
Phase 2 released October 19, 2018. ORR 72% in treatment-naive patients, 39% in previously treated patients.
INC280
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 2b primary and key secondary endpoints met.
Ruxolitinib
Atopic dermatitis
Phase 2 initial data due 2019.
INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2019.
INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2019.
INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Data due 2020.
INCMGA0012
Merkel cell carcinoma
Phase 1 data due 2020.
INCMGA0012
Endometrial cancer
Phase 1/2 initial data due 2019.
INCB53914 and ruxolitinib
Myelofibrosis and Solid Tumors
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 2 data due 2019.
Ruxolitinib
Vitiligo
Phase 1/2 data to be presented 1H 2019.
INCB001158
Solid tumors

Latest News

  1. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  2. Top 10 Healthcare Stories of 2018
  3. See what the IHS Markit Score report has to say about Incyte Corp.
  4. Incyte to Present at Upcoming Investor Conferences
  5. FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
  6. Roche to Create Companion Diagnostic Test for Merck's Keytruda
  7. Why MacroGenics Stock Is Getting Hammered Today
  8. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
  9. Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
  10. Incyte (INCY) Announces Positive Data on Jakafi for GVHD
  11. Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
  12. Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
  13. The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
  14. Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report?
  15. Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
  16. A Look At The Intrinsic Value Of Incyte Corporation (NASDAQ:INCY)
  17. This Highly Rated Pharma Giant Is More Than Just A Diabetes Player

SEC Filings

  1. 8-K - Current report 181203167
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181146953
  3. 8-K - Current report 181145510
  4. 8-K - Current report 181057928
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18981118
  6. 8-K - Current report 18979388
  7. S-8 - Securities to be offered to employees in employee benefit plans 18858193
  8. CT ORDER - Confidential treatment order 18852378
  9. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 18804164
  10. 8-K - Current report 18799581